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Abstract
Few studies have evaluated the association between DNAmethylation in white blood cells (WBC) and the risk
of breast cancer. The evaluation of WBC DNA methylation as a biomarker of cancer risk is of particular
importance as peripheral blood is often available in prospective cohorts and easier to obtain than tumor or
normal tissues. Here, we used prediagnostic blood samples from three studies to analyze WBC DNAmethylation
of two ATM intragenic loci (ATMmvp2a and ATMmvp2b) and genome-wide DNA methylation in long
interspersed nuclear element-1 (LINE1) repetitive elements. Samples were from a case–control study derived
from a cohort of high-risk breast cancer families (KConFab) and nested case–control studies in two prospective
cohorts: Breakthrough Generations Study (BGS) and European Prospective Investigation into Cancer and
Nutrition (EPIC). Bisulﬁte pyrosequencing was used to quantify methylation from 640 incident cases of invasive
breast cancer and 741 controls. Quintile analyses for ATMmvp2a showed an increased risk of breast cancer
limited to women in the highest quintile [OR, 1.89; 95% conﬁdence interval (CI), 1.36–2.64; P¼ 1.64 104]. We
found no signiﬁcant differences in estimates across studies or in analyses stratiﬁed by family history or
menopausal status. However, a more consistent association was observed in younger than in older women
and individually signiﬁcant in KConFab and BGS, but not EPIC. We observed no differences in LINE1 or
ATMmvp2bmethylation between cases and controls. Together, our ﬁndings indicate thatWBCDNAmethylation
levels at ATM could be a marker of breast cancer risk and further support the pursuit of epigenome-wide
association studies of peripheral blood DNA methylation. Cancer Res; 72(9); 2304–13. 2012 AACR.
Introduction
Dysregulation of epigenetic modiﬁcation in tumor DNA
such as hypermethylation of CpG islands at the promoters of
hundreds of genes and global reduction of 5-methylcytosine (5-
mC) levels has been observed in almost every cancer type (1).
However, the roles of epigenetic modiﬁcations as risk factors
for cancer and early disease biomarkers are yet to be deter-
mined (2).
Epigenetic changes such as DNA methylation could be a
biologic indicator of lifetime accumulation of environmental
exposures including ageing (3, 4), hormones (5, 6), ionizing
radiation (7), alcohol (8), smoking (9, 10), and trafﬁc particles
(11). Alternatively, epigenetic changesmightmodify the effects
of genetic susceptibility loci through genotype–epigenotype
interactions, via in cis allele–speciﬁc methylation (12). Some
methylation changes may also reﬂect parental and early-life
exposures that are particularly difﬁcult to measure in epide-
miologic studies of adults (2, 13). Although DNA methylation
proﬁles are often tissue- and cell-speciﬁc, recent data indicate
that epigenetic traits in white blood cells (WBC) are promising
candidate risk markers for solid tumors (14–16). Evaluating
WBC DNA methylation as a biomarker of risk is of particular
interest because peripheral blood DNA is comparatively acces-
sible and is readily available in many large prospective
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epidemiologic studies. Previous reports of WBC DNA methyl-
ation and cancer risk include studies of global DNA methyl-
ation levels in repeat regions across the genome (e.g., LINE1,
Alu) or 5-mC content in genomic DNA (16–20); studies of gene-
speciﬁc DNAmethylation levels in candidate genes (14, 21–29),
and genome-wide DNA methylation microarray studies
(15, 30–32). Although these studies provide enticing ﬁndings,
most included relatively small study populations and/or used
samples collected after diagnosis, thus raising concerns about
reverse causality and the potential confounding inﬂuences of
active disease or treatment on DNA methylation in blood (25).
Most research onDNAmethylation in cancer has focused on
gene promoter CpG islands (CGI). Reasons for this include the
historical identiﬁcation of methylation at the promoters of
tumor suppressor genes in a wide variety of cancers and the
mechanistic association of methylation with transcriptional
repression at these loci (33). However, recent data suggest that
methylation in regions around CpG islands or "shores" and
intragenic sequences also appears to be important in tissue-
speciﬁc expression and may be an important contributor to
interindividual variation in gene expression (34). For example,
using a differential methylation hybridizationmicroarray anal-
ysis of candidate genes in WBC DNA, we showed that the
majority of methylation variability in 55 genes was associated
with intragenic repetitive elements (14). In addition, an intra-
genic differentially methylated region (DMR) within the ATM
gene correlated with gene expression and was signiﬁcantly
more methylated in postdiagnostic blood samples from 190
bilateral breast cancer cases compared with 190 controls (14).
However, global DNA methylation as measured by long inter-
spersed nuclear element-1 (LINE1) repetitive element methyl-
ation was not signiﬁcantly associated with risk. In the present
study, we followed up these ﬁndings to test the hypothesis that
prediagnostic intragenic and global LINE1 repetitive element
methylation is prospectively associated with the risk of breast
cancer using 3 studies with prediagnostic blood samples: the
Kathleen Cuningham Foundation Consortium for Research
into Familial Breast cancer (KConFab) study, a prospective
cohort of families at high risk of breast cancer; and 2 general
population prospective cohorts: the Breakthrough Genera-
tions Study (BGS) and the European Prospective Investigation
into Cancer and Nutrition (EPIC).
Materials and Methods
Study populations
Study participants were drawn from 3 large studies with
blood samples collected before breast cancer diagnosis (Table
1). All contributing studies have appropriate ethical approval
for sample and data collection. The ﬁrst study was provided by
KConFab (35). From 1997 to May 2011, KConFab collected
peripheral blood samples from 12,747 members of 1,395 fam-
ilies (8.8 samples per family) in Australia and New Zealand.
Families had an average of 3 veriﬁed (5.4 unveriﬁed) breast
cancers per family. At the time of sampling, there were 12,747
blood samples collected from breast cancer familymembers of
whom4,305 had a veriﬁed prior cancer diagnosis. All remaining
healthy subjects were screened for subsequent incident cancer
cases which were identiﬁed and conﬁrmed in 1 of 4 ways,
primarily by clinical pathology report, then doctor's notes,
cancer council registry veriﬁcation, or death certiﬁcate. Inci-
dent cases of invasive breast cancer were selected for this study
from all individuals with a breast cancer diagnosis more than 1
month after blood sample collection (n ¼ 171). Five cases of
non-white ethnicity were excluded from the analyses resulting
in 166 invasive cases that were compared with 225 healthy
unrelated controls without a family history of breast cancer
drawn from "best friends" of subjects enrolled in KConFab.
Incident breast cancer cases had blood samples taken, on
average, 45 months before diagnosis (range, 1–140 months).
Information on breast cancer risk factors including hormonal
and reproductive factors, cigarette smoking, and alcohol drink-
ing was collected from questionnaires at enrollment. In addi-
tion, pathology data, including grade (12% grade I, 33% grade II,
40% grade III), nodal status (37% node positive), estrogen
receptor (ER; 63% ER positive, 24% ER negative), progesterone
receptor (PR; 55% PR positive), HER2 status (27% HER2
positive), and BRCA1/2 mutation status (23% BRCA1 mutant,
14% BRCA2 mutant, 63% non-BRCA1/non-BRCA2), were avail-
able for breast cancer cases.
The second study was based on the BGS, a large general
population cohort consisting of approximately 110,000 women
enrolled in the United Kingdom from 2003 to 2011 (36). Study
participants were sampled from a nested case–control study of
all incident cases of breast cancer diagnosed in the BGS up to
June 2010 and controls individually matched on recruitment
source, year of completion of the baseline questionnaire at
enrolment, ethnicity (white only), date of birth within 12
months, availability of blood sample, and duration that the
blood sample was in the mail. Breast cancer cases were self-
reported in a follow-up questionnaire about 2.5 years after
enrollment or notiﬁed by study participants by phone or letter.
Self-reported diagnoses were conﬁrmed through an electronic
linkage with England/Wales/Scotland/Northern Ireland can-
cer registrations (or by the general practitioner for a small
number of cases who could not be successfully linked). Checks
against U.K. cancer registrations were also made for those BGS
participants known to have died by the time of the 2.5-year
follow-up or who otherwise failed to respond to the follow-up
but had given permission for such follow-up. A random sample
of 257 case–control pairs of 534 pairs identiﬁed as of December
2010 was selected for themethylation study. Four controls who
were subsequently found to have had prevalent breast cancer
at study entry, 3 cases whose blood was collected after diag-
nosis, and one case with ductal carcinoma in situ (DCIS) were
excluded from the analyses, resulting in a total of 253 cases and
253 controls available for analyses. Blood samples, from inci-
dent cases, were taken on average 18 months before diagnosis
(range, 0.03–59; Table 1). Extensive information on breast
cancer risk factors was collected from a baseline questionnaire
at enrollment. Pathology information from all cases was not
available at the time of these analyses, available data represent
only 25% of cases and included morphology (78% ductal, 12%
lobular, 10% other), grade (14% grade I, 50% grade II, 36% grade
III), nodal status (33% node positive), ER status (84% ER
positive, 16% ER negative), and HER2 status (19% HER2
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positive). An additional random sample of 92 participants in
the BGS was selected from women enrolled in 2004 with 2
blood samples/questionnaires collected at baseline and ﬁrst
follow-up (6 years after baseline). Additional inclusion cri-
teria included the following: 35–84 years at enrollment, free of
breast cancer before second blood collection, not know to have
a relative in the study, blood samples received at processing
laboratory less than 1 day after collection, expected amount of
blood receipt at the laboratory, no reported problems at
collection or processing (e.g., lipemic, hemolyzed, clotted
samples), and time between the receipt of each sample
between 5.5 and 6.5 years. Paired samples from these women
were analyzed to evaluate the stability of the ATMmvp2a and
LINE1 methylation markers over time.
The third study was provided by the EPIC cohort, a large
general population cohort consisting of about 520,000 indivi-
duals with standardized lifestyle and personal history ques-
tionnaires, anthropometric data and blood samples collected
for DNA extraction (37). Study participants were sampled in 2
groups including a group of premenopausal women (145 cases
and 145 controls) and postmenopausal women (139 cases and
146 controls), with menopausal status deﬁned at the time of
blood collection. Controls were individually matched on age at
baseline, recruitment centre, and date and time of blood
collection. DCIS cases were excluded from analyses (n ¼
36), resulting in a total of 248 cases and 291 controls available
for analyses (Table 1).Wedid not have precise ethnicity data on
these individuals; however, the majority (80%) of individuals
were provided from Italy, Spain, and the Netherlands and the
remainder (20%) from France, Germany, United Kingdom, and
Greece. Blood samples from cases were taken on average 55
months before diagnosis (range, 24–108); Table 1). Extensive
information on cancer risk factors, including extensive alcohol,
smoking and dietary data, family history, and hormonal fac-
tors, was collected from a baseline questionnaire at enroll-
ment. Pathology information on cases included morphology
(73% ductal, 14% lobular, 13% other), grade (15% grade I, 65%
grade II, 20% grade III), stage, ER (79% ER positive, 21% ER
negative), PR (62% PR positive, 38% PR negative), and HER2
status (20% HER2 positive).
Laboratory methods
DNAsamples were extracted fromwhole blood usingQiagen
DNA BloodMini Kits in KConFab. DNA samples from BGS and
EPIC were extracted from buffy coats using DNA Blood Mini
Kits (Qiagen), except for 29 cases and 15 controls in BGS
extracted using Nucleon Genomic DNAExtraction Kit (Tepnel,
Life Sciences). Five hundred nanograms of DNA (KConFab) or
250 ng (BGS and EPIC studies) from each subject was bisulﬁte-
converted using EZ-96 DNAMethylation-Gold kit according to
the manufacturer's protocol (Zymo Research). Methylation
analysis of LINE1 was analyzed using commercially available
LINE1 primers (Qiagen). Primers and PCR conditions for
ATMmvp2a and ATMmvp2b regions were as described previ-
ously (14). Methylation values were calculated as an average of
all high-quality CpG sites (determined as "passed" by the
quality control thresholds within the Pyro Q-CpG Software;
Qiagen). The Pyro Q-CpG Software has inbuilt overall quality
assessment for each sample which ﬂags any sequence that
deviates from the expected pattern. Any sample failing quality
control was removed from the analysis. The number of samples
failing in each assay were ATMmvp2a (55 of 1,436 subjects),
ATMmvp2b (56 of 1,436 subjects), and LINE1 (87 of 1,436
subjects). In addition, a commercially available fully methyl-
ated genomic DNA sample was used as a positive control
(Zymo Research) and in-house whole genome ampliﬁed geno-
mic DNA (Genomiphi, GE Healthcare) used as an unmethy-
lated negative control. The percentage of cells withmethylated
DNA at each of the loci was calculated as the average of 3
(ATMmvp2a) or 4 (LINE1 and ATMmvp2b) CpG sites and was
Table 1. Characteristics of the study populations
KConFab BGSa EPICb
Controls Cases Controls Cases Controls Cases
N 225 166 253 253 291 248
Age at blood draw, mean (range), y 60 (33–83) 50 (21–91) 54 (23–82) 54 (23–82) 52 (33–76) 52 (33–76)
Family history, n (%)
Yes 0 (0) 166 (100) 51 (20) 69 (27) 24 (14) 23 (18)
No 225 (100) 0 (0) 201 (80) 183 (73) 144 (86) 108 (82)
Menopausal status at blood draw, n (%)
Premenopausal 37 (17) 101 (65) 135 (61) 134 (62) 145 (50) 127 (50)
Postmenopausal 183 (83) 54 (35) 87 (39) 83 (38) 146 (50) 121 (50)
Time from blood collection to
diagnosis, mean (range), mo
— 45 (1–140) — 18 (<1–59) — 55 (24–108)
Age at diagnosis, mean (range) — 52 (29–88) — 55 (23–84) — 57 (37–80)
aCases were individually matched to controls for recruitment source, year of completion of the baseline questionnaire at enrolment,
ethnicity, availability of blood sample, date of birth within 12 months, and duration that the blood sample was in the mail.
bCases and controls were selected within strata of menopausal status (pre and post) and individually matched on age, recruitment
centre, and date and time of blood collection.
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used as the measure of methylation for each subject. On the
basis of previous experimental results, the range for a typical
assay is 90% to 98% for the positive control and 1% to 6% for the
negative control. Further quality assurance was conducted
with blinded duplicate samples (12 pairs, 2 pairs within each
plate) with median differences of 3.5%, 4.1%, and 1.8% in the
BGS duplicates and 2.1%, 1.7%, and 1.3% in the positive and
negative controls on each plate for ATMmvp2a, ATMmvp2b,
and LINE1, respectively. The intraclass correlation (ICC) for
the 12 blinded duplicates was 0.56 [95% conﬁdence interval
(CI), 0.26–0.96], 0.37 (95% CI, 0–0.76), and 0 (95% CI, 0–0.61) for
ATMmvp2a, ATMmvp2b, and LINE1, respectively. It should be
noted that the low ICCs for ATMmvp2b and LINE1 are due to a
relatively low between subject variation, rather than large
assay variation.
Statistical analysis
The Wilcoxon test for matched pairs was used for BGS and
EPIC and the Mann–Whitney U test was used for KConFab, to
test for differences inmedianmethylation levels between cases
and controls. Levels of methylation across studies were stan-
dardized using Z-scores that were categorized in quintiles on
the basis of their distribution in the combined control popu-
lation. Logistic regression was used to estimate ORs and 95%
CIs for individuals in the second, third, fourth, and ﬁfth
methylation quintiles, compared with individuals in the ﬁrst
(lowest) quintile. Analyses of combined data from all studies
were adjusted by age in 5-year categories and study. Age at
blood draw, age atmenarche, parity, age atmenopause, alcohol
consumption, body mass index, oral contraceptive and hor-
mone replacement use, and family history of breast cancer
were considered as potential confounders. Analyses were
stratiﬁed by age at blood drawn using tertiles of the combined
control population (21–49,>49–59,>59–91), family history, and
time from blood collection to diagnosis to evaluate effect
modiﬁcation by these variables. Estimates from conditional
logistic regression models for individually matched pairs in
BGS (n ¼ 241 pairs after quality control) and EPIC (n ¼ 221
pairs after quality control) were similar to estimates from
unconditional logistic models adjusted or unadjusted by
matching factors. Only ﬁndings from the unconditional logistic
analyses are presented to avoid loss of data from exclusion of
pairs with one member excluded because of missing methyl-
ation data or other reasons (see Study populations). Hetero-
geneity of estimates by study was tested by including an
interaction term for the biomarker and an indicator variable
for study in the logisticmodel. Random-effectmeta-analyses of
estimated ORs from all studies in this report and a previously
published study were conducted in R using the "metafor"
package (38). Polytomous logistic regression models with
categories of methylation levels as the outcome variable were
used to test for associations between methylation levels and
the breast cancer risk factors speciﬁed above, adjusted for age.
B-spline quadratic logistic regressionmodelsﬁtted in the "bs" R
package were used to explore the relationship between con-
tinuous measures of methylation levels and breast cancer risk.
All statistical tests were conducted using R (v 2.12.0).
Results
For the ATMmvp2a locus, we observed signiﬁcantly higher
median methylation in cases than controls in the familial
samples from KConFab (81.8% vs. 76.9%, P ¼ 4.87 
106; Table 2) and marginally higher median methylation in
the population-based cases from BGS than in controls (76.8%
vs. 76.4%, P ¼ 0.02). In the EPIC cohort, we observed no
signiﬁcant differences in median methylation levels in cases
compared with controls (75.7% vs. 76.1%, P¼ 0.40). In BGS and
KConFab, we observed an upward shift in the distribution of
methylation in cases compared with controls, which was not
observed in EPIC (Supplementary Fig. S1). No signiﬁcant
Table 2. Distribution of methylation levels in ATMmvp2a, ATMmvp2b, and LINE1 in breast cancer cases
and controls
Control Case Control Case
Assay Study na na Median (IQR) Median (IQR) Pb
ATMmvp2a BGS 248 249 76.4 (70.2–80.2) 76.8 (70.9–82.7) 0.02
EPIC 283 235 76.1 (70.5–80.6) 75.7 (70.0–80.8) 0.40
KConFab 210 156 76.9 (71.6–81.5) 81.8 (75.8–86.5) 4.87  106
ATMmvp2b BGS 234 248 91.0 (87.0–94.8) 91.4 (85.6–95.0) 0.61
EPIC 287 240 92.2 (87.3–95.2) 92.3 (88.3–95.7) 0.36
KConFab 208 162 92.6 (87.2–96.3) 92.3 (82.4–96.5) 0.24
LINE1 BGS 242 241 79.0 (77.9–80.1) 79.0 (78.1–79.9) 0.96
EPIC 263 232 75.1 (73.9–76.3) 75.2 (73.9–76.3) 0.89
KConFab 218 153 76.0 (74.3–78.0) 76.6 (75.2–77.6) 0.20
NOTE: Bold signiﬁes P < 0.05.
Abbreviation: IQR, interquartile range.
aDifferences in numbers of cases and controls within each study with total numbers are due to missing data (failed quality control) on
methylation markers.
bWilcoxon matched pairs test for BGS and EPIC and Mann–Whitney U test for KConFab.
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differences were found for methylation levels at the
ATMmvp2b locus (131 bp downstream from ATMmvp2a) or
LINE1 in any of the studies (Table 2).
Quintile analyses for the ATMmvp2a locus, adjusted by
age at blood collection in 5-year categories, showed a
signiﬁcantly increased risk of breast cancer for women in
the highest quintile compared with the lowest quintile in the
BGS and KConFab studies, but not in EPIC (Table 3). Further
adjustment by age as continuous variable and conditional
logistic analyses for paired samples individually matched in
BGS and EPIC showed similar results (Supplementary Table
S1). Analyses of combined data from all studies adjusting by
study and age at blood collection indicated that women in
the highest quintile (>6.3% methylation above study mean
methylation) were at 1.9-fold increased risk of breast cancer
compared with women in the lowest quintile (OR, 1.89; 95%
CI, 1.36–2.64; P ¼ 1.64  104; Table 3). While the overall
difference in median levels between cases and controls was
small (1.1%), the difference in median methylation between
the highest quintile (86%) and lowest (65%), where the
association with cancer status is observed, was large
(21%). A quadratic B-spline regression model of continuous
levels of methylation at ATMmvp2a and breast cancer risk
conﬁrmed a threshold association, rather than a linear
association, between methylation levels and breast cancer
risk (Supplementary Fig. S2).
Study-adjusted analyses stratiﬁed by age at blood collection
suggested a weaker ATMmvp2a risk association when meth-
ylation was measured in samples collected from women older
than 59 years (Table 4). Similar results were obtained when
stratiﬁed by age at diagnosis (data not shown). However, age-
speciﬁc estimates within study revealed that the weaker asso-
ciation was driven by the EPIC cohort that showed no
increased risk in this age subgroup (Supplementary Fig. S3).
Overall analyses showed some evidence for heterogeneity of
estimates between studies (Table 3; P value for test for het-
erogeneity¼ 0.07). This evidence was limited to women in the
older age group and there was no evidence for study
Table 3. Association between methylation levels in ATMmvp2a and breast cancer risk in BGS, EPIC,
KConFab, and combined analysis
Controls Cases
Study Quintilea Methylation range N Freq. N Freq. ORb (95% CI) P
BGS Qi1 3.4%–68.0% 50 0.20 35 0.14 1.00
Qi2 68.0%–74.1% 40 0.16 46 0.18 1.56 (0.85–2.88) 0.15
Qi3 74.1%–77.6% 54 0.22 47 0.19 1.15 (0.66–2.16) 0.54
Qi4 77.6%–81.0% 56 0.23 42 0.17 1.00 (0.55–1.81) 0.99
Qi5 81.0%–91.7% 48 0.19 79 0.32 2.31 (1.31–4.06) 3.7  103
Totals 248 249
EPIC Qi1 53.6%–69.7% 60 0.21 49 0.21 1.00
Qi2 69.7%–74.8% 61 0.22 51 0.22 1.02 (0.60–1.74) 0.96
Qi3 74.8%–78.6% 58 0.19 46 0.20 0.97 (0.56–1.67) 0.97
Qi4 78.6%–82.4% 49 0.17 38 0.16 0.95 (0.54–1.68) 0.95
Qi5 82.4%–97.5% 55 0.19 51 0.22 1.13 (0.66–1.94) 0.76
Totals 283 235
KConFab Qi1 19.0%–70.2% 38 0.18 20 0.13 1.00
Qi2 70.2%–75.4% 47 0.22 16 0.10 0.55 (0.25–1.25) 0.15
Qi3 75.4%–79.1% 36 0.17 22 0.14 1.11 (0.51–2.44) 0.80
Qi4 79.1%–83.0% 43 0.20 31 0.20 1.40 (0.67–2.95) 0.37
Qi5 83.0%–100% 46 0.22 67 0.43 3.06 (1.53–6.10) 1.5  103
Totals 210 156
Combined Qi1 71.3% to 6.5% 148 0.20 104 0.16 1.00
Qi2 6.5 to 1.2% 148 0.20 113 0.18 1.08 (0.76–1.54) 0.64
Qi3 1.2 to 2.5% 148 0.20 115 0.18 1.09 (0.77–1.54) 0.64
Qi4 2.5%–6.3% 148 0.20 111 0.17 1.06 (0.74–1.51) 0.75
Qi5 6.3%–23.3% 149 0.20 197 0.31 1.89 (1.36–2.64) 1.6  104
Totals 741 640
NOTE: Bold, statistically signiﬁcant results, P < 0.05.
aCutoff values determined by quintiles of Z-scores based on the distribution in the combined control population. Z-score cutoff values
are 0.83, 0.24, 0.19, and 0.64.
bORs within each study are adjusted by 5-year age categories, with further adjustment by menopausal status in EPIC to account for
stratiﬁed sampling. ORs in combined analyses are adjusted by 5-year age categories and study (with EPIC deﬁned by 2 categories of
menopausal status to account for stratiﬁed sampling).
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heterogeneity within the younger age subgroups [P value for
study heterogeneity by age subgroups 21–49 (P ¼ 0.51), 50–59
(P ¼ 0.72), 60–91 years (P ¼ 0.09)]. We observed a signiﬁcant
association between ATMmvp2a methylation levels and
increasing age at blood collection in controls (Spearman's r
¼ 0.15, P¼ 0.0015), but not in cases (Spearman's r¼0.02, P¼
0.43), that was most signiﬁcant in the EPIC cohort (r¼ 0.11, P
¼ 0.007) compared with KConFab (r¼ 0.06, P¼ 0.26) and BGS
(r ¼ 0.02, P ¼ 0.40). This underlying age association may
account for the apparent cross-over risk association with ATM
methylation by age at blood collection seen in EPIC (Supple-
mentary Fig. S3). Analyses by menopausal status at blood
collection, adjusted by study and age, showed similar risk
estimates for pre- and postmenopausal women (Supplemen-
tary Table S2).
Adjustment by breast cancer risk factors (age at menarche,
menopausal status at blood drawn, parity, age at menopause,
alcohol consumption, bodymass index, oral contraceptive and
hormone replacement use, and family history of breast cancer)
did not result in appreciable changes in relative risk estimates
for any of the markers across the 3 studies in this report.
Consistently, these risk factors were not signiﬁcantly associ-
atedwith ATMmvp2amethylation levels in any of the 3 control
populations (data not shown). In the familial cases from
KConFab, we found no signiﬁcant associations between
ATMmvp2a methylation levels and BRCA1/2 mutation status,
tumor pathology (morphology, grade, nodal, ER, PR, and HER2
status; data not shown). Similarly, in EPIC andBGS samples, we
found no signiﬁcant association with available data on tumor
pathology (data not shown).
Analyses stratiﬁed by time from blood collection to diag-
nosis ( 1 vs. >1 year) showed no signiﬁcant differences in
effect estimates using the combined data (Supplementary
Table S3). Consistently, linear regression analyses of methyl-
ation levels and time from blood collection to diagnosis,
adjusted by age, showed no signiﬁcant associations (KConFab,
P¼ 0.97; BGS, P¼ 0.10; EPIC, P¼ 0.28), over the range of 0 to 11
years studied here.
A biomarker for risk that is observed only at one time point
(as is the case withmost case–control studies) would ideally be
stable over time. We measured the stability of the ATMmvp2a
marker and LINE1 by assessing methylation in a control
population where blood samples were taken 6 years apart
from the same individuals in the BGS cohort (n ¼ 92 pairs).
Using conditional logistic regression, we observed no signiﬁ-
cant change in either ATMmvp2a (median change ¼ 0.19%,
P ¼ 0.51) or LINE1 (median change ¼ 0.27%, P ¼ 0.69) over
6 years. The ATM variation between individuals is much larger
than within individuals at 2 time points (ICC ¼ 0.57; between
time points correlation, R2¼ 0.79) and there are no signiﬁcant
Table 4. Associationbetweenmethylation levels inATMmvp2aandbreast cancer risk in combinedanalysis
stratiﬁed by age at blood draw
Controls Cases
Case proportions by study
Age range, y Quintiles N Freq. N Freq. (K, B, E)a ORb (95% CI) P
21–49 Qi1 45 0.21 44 0.17 0.20, 0.27, 0.52 1.00
Qi2 51 0.23 39 0.15 0.28, 0.26, 0.46 0.68 (0.37–1.25) 0.21
Qi3 44 0.20 41 0.16 0.27, 0.32, 0.41 0.94 (0.51–1.72) 0.83
Qi4 38 0.18 44 0.17 0.43, 0.18, 0.39 1.00 (0.54–2.17) 0.99
Qi5 39 0.18 90 0.35 0.40, 0.33, 0.27 2.07c (1.16–3.68) 0.01
Total 217 258 0.33, 0.28, 0.38
>49–59 Qi1 54 0.20 27 0.13 0.19, 0.41, 0.41 1
Qi2 55 0.20 43 0.21 0.05, 0.49, 0.47 1.57 (0.84–2.91) 0.15
Qi3 62 0.23 48 0.24 0.19, 0.38, 0.44 1.56 (0.85–2.86) 0.15
Qi4 50 0.19 33 0.16 0.09, 0.48, 0.42 1.26 (0.66–2.41) 0.48
Qi5 49 0.18 53 0.26 0.19, 0.49, 0.32 2.25c (1.21–4.17) 0.01
Total 270 204 0.14, 0.45, 0.41
>59–91 Qi1 49 0.19 33 0.19 0.18, 0.36, 0.45 1.00
Qi2 42 0.17 31 0.17 0.10, 0.48, 0.42 1.00 (0.51–1.97) 0.99
Qi3 42 0.17 26 0.15 0.08, 0.62, 0.31 0.84 (0.45–1.58) 0.61
Qi4 60 0.24 34 0.19 0.26, 0.53, 0.21 0.80 (0.45–1.45) 0.50
Qi5 61 0.24 54 0.31 0.39, 0.43, 0.19 1.39c (0.87–2.26) 0.27
Total 254 178 0.23, 0.47, 0.30
NOTE: Bold, statistically signiﬁcant results, P < 0.05.
aStudy proportions for KConFab (K), BGS (B), and EPIC (E) contributing to each quintile in each age group.
bORswithin each age group are adjusted by study. Test for heterogeneity of effects by age group in combined analysis,P¼ 0.3109 for
Qi5 versus Qi1.
cP values for study heterogeneity for ORs comparing Qi5 versus Qi1 within age subgroups: 21–49 years (P ¼ 0.51), 50–59 years
(P ¼ 0.73), and 60–91 years (P ¼ 0.09).
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differences between measurements in the 2 time points
(paired t test, P ¼ 0.24; signed test for H0:median difference
¼ 0, P ¼ 0.74). These data show that the ATM methylation
is stable for at least 6 years.
Wepreviously reported a quartile analysis of theATMmvp2b
region in bilateral patients with breast cancer who showed a 3-
fold higher chance of being a breast cancer case comparedwith
healthy controls in the highest quartile (14). We have now
reanalyzed these data for both loci (ATMmvp2a and
ATMmvp2b) using a quintile analysis for direct comparison
with the present study. This analysis shows that women in the
highest quintile of methylation had increased bilateral breast
cancer risk for both ATMmvp2a (age-adjusted OR, 1.90; 95%CI,
1.00–3.62; P ¼ 0.05) and ATMmvp2b (age-adjusted OR, 3.07;
95% CI, 1.58–5.93; P ¼ 8.8  104; Supplementary Table S4). A
meta-analysis of OR estimates including the 3 additional
studies and the study of bilateral breast cancer cases, suggested
that the methylation levels in the ATMmvp2a marker are
associated with 1.89-fold OR (95% CI, 1.27–2.82; P ¼ 1.7 
103, random-effects model) for women in the ﬁfth quintile
compared with the ﬁrst quintiles (Fig. 1), with no signiﬁcant
heterogeneity between studies (P ¼ 0.15).
Discussion
Our ﬁndings indicate that high levels of methylation in the
ATM DMR might be a biomarker of breast cancer risk. To our
knowledge, this is the ﬁrst report to identify a signiﬁcant
association between breast cancer risk and gene-speciﬁc
methylation in WBC DNA measured in prediagnostic blood
samples from cases in prospective cohorts and using pyrose-
quencing which is a highly quantitative method.
Previous studies investigating peripheral blood methylation
variability in relation to cancer risk have focused mainly on
rare epimutations or genome-wide methylation levels (25, 39).
Only a few studies have investigated gene-speciﬁc DMRs and
all of these have been carried out in small retrospective studies
or used nonquantitative methods (26–29). This includes our
initial report of the association between ATM hypermethyla-
tion in WBC DNA and increased breast cancer risk using
retrospectively collected blood samples from bilateral patients
with breast cancer (14). While ﬁndings for ATMmvp2a were
consistent with those in this report, the strong association
found for ATMmvp2b in the bilateral study was not replicated.
Differences in ﬁndings could be due to the different designs
and study populations, for example, use of pre- versus post-
diagnostic blood samples, source of control populations, and
inclusion of incident versus prevalent cases, or bilateral versus
mostly unilateral breast cancers.
The main strength of the current report is the inclusion of 3
independent study populations. Although we found no signif-
icant heterogeneity in ATMmvp2a risk associations across
studies, the evidence was strongest for KConFab and weaker
for the BGS and, particularly, for the EPIC cohort. The stronger
association in KConFab could be explained by the inclusion of
cases with very strong family histories, and/or to the choice of
controls that were selected from best friends of KConFab
participants, and had no family history of breast cancer. In
contrast, BGS and EPIC are nested case–control studies within
2 general population cohorts, thus ensuring that cases and
controls come from the same source population. We observed
a weak correlation between increasing methylation and
increasing age at blood draw in the control populations, as
has been shown for numerousmethylationmarkers in blood (3,
4). The age correlation was particularly strong in the EPIC
cohort, which might explain that the risk association in this
cohort was not seen in women with blood collected at older
ages. It is important to note that breast cancer cases in
KConFab were younger than controls; therefore, if there was
no real association with risk, an association between increas-
ing age at blood collection and increasing methylation would
result in an observed inverse association, rather than a positive
association that we found. The fact that the ATM risk associ-
ationwasmost robust and consistent across studies forwomen
with bloods collected in younger ages suggests that this ﬁnding
may be more applicable to women in this group or to breast
cancer cases with earlier onset. However, additional data are
needed to conﬁrm this potential effect modiﬁcation by age as
differenceswere not statistically signiﬁcant in our analyses.We
can speculate that if ATM hypermethylation is associated with
an endogenous increased risk of breast cancer, then it is
plausible that it would be more frequent in earlier onset breast
cancer cases, similar to genetic mutations, and we would thus
have an ascertainment bias toward ﬁnding this association in
younger than in olderwomen. Larger sample sizes from studies
with long follow-up will be required to separate out the
associations among women with blood drawn at a young age
from those associated with earlier onset breast cancer.
The use of prediagnostic samples from incident breast
cancer cases in this report excludes the possibility that meth-
ylation variability inWBCDNAwas inﬂuenced by the presence
of clinical cancer or treatment in these patients. Furthermore,
we found no association between time fromblood collection to
diagnosis and level of ATM methylation, indicating that
Test for heterogeneity: Q (df = 3) = 5.3232, P = 0.1496
OR
Combined (RE model) 
8.083.901.880.900.44
KConFab
EPIC
BGS
BBCS‡
3.06 (1.53–6.10)
1.13 (0.66–1.94)
2.31 (1.31–4.06)
1.90 (1.00–3.62)
1.89 (1.27–2.82)
Figure 1. Meta-analysis of ATM methylation in 4 case–control studies. A,
methylation levels at ATMmvp2a were separated into control quintile
ranges (using identical ranges fromcombined analysis), for the previously
published report on the British Breast Cancer Study (BBCS z; ref. 14) and
the 3 new case–control studies. ORs of Qi5 versus Qi1 are shown.
Combined overall analysis was determined using a random-effects (RE)
model.
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ﬁndings are unlikely to be explained by preclinical disease
effects (range of time from blood collection to diagnosis in our
studies was <1 month to 11 years). Furthermore, using serial
blood samples taken 6 years apart, we have shown that this
marker appears to be stable over time. Thus, data suggest that
ATM hypermethylation in WBC DNA represents a stable
marker of predisposition rather than an early tumorigenic
event that increases with increasing tumor burden.
The strongest association between ATM methylation and
breast cancer risk was observed in the KConFab study which is
a familial breast cancer cohort that includes an overrepresen-
tation of BRCA1 and BRCA2 mutation carriers. We have
previously shown that BRCA1mutant tumors havemuch lower
levels of gene-speciﬁc hypermethylation than non-BRCA1/2 or
BRCA2 mutant tumors (40). This suggests that BRCA1 muta-
tions may lead to an overall disturbance in methylation
patterns. To support this hypothesis, a recent study has shown
that young girls with a strong family history of breast cancer
have signiﬁcantly lower levels of WBC DNA methylation of
ALU and LINE1 repetitive elements than young girls without
a strong family history (41). However, in contrast to this
ﬁnding, we found no differences between methylation levels
of LINE1, or ATM in carriers of BRCA1 (n ¼ 39), BRCA2 (n ¼
23) mutations compared with noncarriers (n ¼ 104) in the
KConFab adult cases (data not shown). In addition, we
found no association between methylation in LINE1 or ATM
and family history of breast cancer in BGS and EPIC controls
(data not shown), thus not supporting a strong association
between methylation and family history. Further work on
larger numbers of mutation carriers will be required to
determine whether these do indeed have an overall aberrant
methylation defect.
The association between breast cancer risk andmethylation
of an intragenic repetitive element in ATM is consistent with a
previous study in which themajority of cancer-associated CpG
sites were found in intragenic sequences (42). Furthermore, we
have previously shown that greater methylation variability
occurs within gene bodies than within promoters (14). Several
hypotheses have been proposed for how intragenic DNA
methylation regulates transcription via mechanisms including
transcription rate, nucleosome positioning, alternate start
sites, replication timing, or chromatin marks (42). Therefore,
these data raise the possibility that variation in gene expression
and indeed cancer susceptibility may be more likely to be
inﬂuenced by themore variable DNAmethylation in intragenic
repetitive elements than less variable methylation at CpG
islands.
The mechanism by which methylation at ATMmvp2a could
increase risk is not known.Wehave previously shown in cancer
cell lines that hypermethylation of the nearby locus
ATMmvp2b is associated with reduced ATM expression (14),
but expression analysis in cell lines and blood samples is
needed to examine the effect of ATMmvp2a hypermethylation
on ATM expression. Interestingly, expression of ATM in WBCs
of patients with breast cancer and controls, at the time of
mammographic screening, showed signiﬁcantly reduced
expression in patients with breast cancer (n ¼ 51) compared
with controls (n¼ 31) in a recent study (ref. 43; Supplementary
Fig. S4). These data support the hypothesis that reduced
expression of ATM, detectable in WBCs, may be linked to
breast cancer susceptibility.
Genome-wide DNA hypomethylation has been linked to
bladder cancer risk in 3 relatively large case–control studies
(285–775 cases; refs. 16–18). In addition, genome-wide hypo-
methylation has been linked to the risk of head and neck
squamous cell carcinoma (19), whereas 2 relatively small
studies (40 cases vs. 40 controls and 179 cases vs. 180
controls) suggested an association with breast cancer
(20, 39). In our previous study, we showed no signiﬁcant
difference between 190 breast cancer cases and 190 controls
using the LINE1 repetitive element in WBC DNA methylation
(14). Consistent with these ﬁndings, we found no evidence of
association between LINE1 methylation and breast cancer
risk in any of the 3 studies in this report. The lack of
association between methylation levels in LINE1, and also
ATMmvp2b, might be explained by the low between-subject
variation observed in the populations under study relative to
the total variation (thus resulting in low ICCs for these 2
assays). Inconsistencies between our ﬁndings and those
reporting associations between blood genome-wide hypo-
methylation and cancer risk may be due to smaller sample
sizes (20, 39), the use of postdiagnostic DNA samples in
previous studies (20, 39), different cancer types (16–18), and
different methods using other repetitive elements (20, 39) or
total 5-mC (16–18).
In conclusion, our ﬁndings on the association between ATM
hypermethylation inWBCDNAbefore diagnosis and the risk of
developing breast cancer provide further support for the
investigation of common epigenetic variability as risk markers
for breast and other cancers. In addition to candidate-gene
studies, epigenome-wide association studies (EWAS) are now
possible with the development of high-throughput technology
that allows high-resolution analysis on a genomic level
(15, 32, 44). However, adequately powered studies with blood
samples collected before diagnosis will be critical for the
success of both candidate- and epigenome-wide approaches
to discover epigenetic biomarkers of cancer risk.
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